Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001), NCT02889978
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study is to collect biological samples from donors with a new diagnosis of cancer (blood and tumor tissue) and from donors who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer subjects and to develop models for distinguishing cancer from non-cancer.
MORE DETAILS ON THIS GENERAL CANCER TRIAL
16140 / GRAIL-001 / NCT02889978 / Open 7-14-2017
AVAILABLE AT THESE LOCATIONS